$MTVA
MetaVia Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008767 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.955M $2.190M
YoY Change -10.73% -15.77%
% of Gross Profit
Research & Development $920.0K $1.143M
YoY Change -19.51% -46.84%
% of Gross Profit
Depreciation & Amortization $12.00K $12.00K
YoY Change 0.0% 20.0%
% of Gross Profit
Operating Expenses $920.0K $1.143M
YoY Change -19.51% -75.94%
Operating Profit -$2.875M -$3.330M
YoY Change -13.66%
Interest Expense $0.00 $10.00K
YoY Change -100.0% -50.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$2.875M -$3.324M
YoY Change -13.51% -29.73%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.875M -$3.324M
YoY Change -13.51% -29.73%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.15
Diluted Earnings Per Share -$0.11 -$0.15
COMMON SHARES
Basic Shares Outstanding 26.66M 21.62M
Diluted Shares Outstanding 26.66M 21.62M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.56M $13.04M
YoY Change -11.37% 33.06%
Cash & Equivalents $11.60M $13.04M
Short-Term Investments
Other Short-Term Assets $1.707M $860.0K
YoY Change 98.49% -39.01%
Inventory
Prepaid Expenses $1.707M
Receivables
Other Receivables
Total Short-Term Assets $13.26M $13.89M
YoY Change -4.51% 23.91%
LONG-TERM ASSETS
Property, Plant & Equipment $98.00K $270.0K
YoY Change -63.7% -15.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $197.0K $270.0K
YoY Change -27.04% -18.18%
TOTAL ASSETS
Total Short-Term Assets $13.26M $13.89M
Total Long-Term Assets $197.0K $270.0K
Total Assets $13.46M $14.16M
YoY Change -4.94% 22.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $776.0K $470.0K
YoY Change 65.11% -62.99%
Accrued Expenses $693.0K $480.0K
YoY Change 44.38% -80.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.496M $940.0K
YoY Change 59.15% -74.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $37.00K $70.00K
YoY Change -47.14% -22.22%
Total Long-Term Liabilities $37.00K $70.00K
YoY Change -47.14% -22.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.496M $940.0K
Total Long-Term Liabilities $37.00K $70.00K
Total Liabilities $1.533M $1.010M
YoY Change 51.78% -73.42%
SHAREHOLDERS EQUITY
Retained Earnings -$84.70M
YoY Change
Common Stock $27.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.93M $13.15M
YoY Change
Total Liabilities & Shareholders Equity $13.46M $14.16M
YoY Change -4.94% 22.7%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.875M -$3.324M
YoY Change -13.51% -29.73%
Depreciation, Depletion And Amortization $12.00K $12.00K
YoY Change 0.0% 20.0%
Cash From Operating Activities -$4.829M -$6.141M
YoY Change -21.36% 48.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 9.092M
YoY Change -100.0% 18084.0%
NET CHANGE
Cash From Operating Activities -4.829M -6.141M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 9.092M
Net Change In Cash -4.829M 2.951M
YoY Change -263.64% -172.15%
FREE CASH FLOW
Cash From Operating Activities -$4.829M -$6.141M
Capital Expenditures $0.00
Free Cash Flow -$6.141M
YoY Change 48.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26661771
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21615626
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001638287
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26661771
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26661771
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Trading Symbol
TradingSymbol
NRBO
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37809
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
NeuroBo Pharmaceuticals, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2389984
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Berkeley Street, Office 19th Floor
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2022Q1 dei City Area Code
CityAreaCode
857
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
702-9600
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26661771
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11557000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16387000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1707000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
197000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
13264000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
16584000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
99000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
105000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
98000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2022Q1 us-gaap Assets
Assets
13461000
CY2021Q4 us-gaap Assets
Assets
16799000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
776000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
830000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
693000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1301000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1496000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2157000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45000
CY2022Q1 us-gaap Liabilities
Liabilities
1533000
CY2021Q4 us-gaap Liabilities
Liabilities
2202000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26661771
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26661771
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
27000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96601000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96394000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84703000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81828000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11928000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14597000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13461000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16799000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
920000
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1143000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1955000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2187000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
2875000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
3330000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2875000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3330000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2875000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3324000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2875000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3324000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2876000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3331000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26661771
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21615626
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7203000
CY2021Q1 nrbo Stock And Warrants Issued During Period Value
StockAndWarrantsIssuedDuringPeriodValue
10000000
CY2021Q1 nrbo Adjustments To Additional Paid In Capital Transaction Costs In Connection With Equity Financing
AdjustmentsToAdditionalPaidInCapitalTransactionCostsInConnectionWithEquityFinancing
908000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
187000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-7000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3324000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
13151000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14597000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
207000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2875000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11928000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2875000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3324000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
207000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
187000
CY2022Q1 nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
6000
CY2021Q1 nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
5000
CY2022Q1 us-gaap Depreciation
Depreciation
12000
CY2021Q1 us-gaap Depreciation
Depreciation
12000
CY2022Q1 nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
1510000
CY2021Q1 nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
265000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-54000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2106000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-615000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-650000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4829000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6141000
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
10000000
CY2021Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
908000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9092000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4829000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2951000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16387000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10089000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11557000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13035000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11600000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11600000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84700000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's condensed consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgements about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2022Q1 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
446000
CY2021Q4 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
854000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
174000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
376000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
37000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
59000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
72000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
64000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
221000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
221000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
123000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
111000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
98000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
36000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
693000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1301000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
24000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
32000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16000
CY2022Q1 nrbo Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
0.025
CY2022Q1 nrbo Royalty Payment Accrued
RoyaltyPaymentAccrued
0
CY2019Q4 nrbo Percentage Of Proceeds From Grant Sale Or Transfer Of Rights
PercentageOfProceedsFromGrantSaleOrTransferOfRights
0.80
CY2019Q4 nrbo Percentage Of Proceeds From Grant Sale Or Transfer Of Rights
PercentageOfProceedsFromGrantSaleOrTransferOfRights
0.80
CY2021Q1 nrbo Percentage Of Proceeds From Grant Sale Or Transfer Of Rights
PercentageOfProceedsFromGrantSaleOrTransferOfRights
0.10
CY2022Q1 nrbo Milestones Accrued
MilestonesAccrued
0
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6846633
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6885748
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
974999
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.99
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
40000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.02
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
33334
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.04
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
981665
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.80
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
981665
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.80
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
203332
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.86
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.807
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0172
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001558370-22-008767-index-headers.html Edgar Link pending
0001558370-22-008767-index.html Edgar Link pending
0001558370-22-008767.txt Edgar Link pending
0001558370-22-008767-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrbo-20220331.xsd Edgar Link pending
nrbo-20220331x10q.htm Edgar Link pending
nrbo-20220331x10q_htm.xml Edgar Link completed
nrbo-20220331xex31d1.htm Edgar Link pending
nrbo-20220331xex32d1.htm Edgar Link pending
nrbo-20220331_cal.xml Edgar Link unprocessable
nrbo-20220331_def.xml Edgar Link unprocessable
nrbo-20220331_lab.xml Edgar Link unprocessable
nrbo-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending